Rocket Pharmaceuticals, Inc.
RCKT Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$2.29
KIRA · Stoqly’s AI analyst, in plain words
- Rocket Pharmaceuticals, Inc. had $0.0M of revenue in fiscal 2025.
- Rocket Pharmaceuticals, Inc. lost $223M in fiscal 2025.
- Free cash flow was −$190M in fiscal 2025, — of revenue.
Market cap
$262M
P/E
—
Revenue
$0.0M
Net income
−$223M
Free cash flow
−$190M
Operating margin
—
Rocket Pharmaceuticals, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$223M
No. It lost money last year.
How healthy are the accounts?
1 / 7
Weak. It passes 1 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Rocket Pharmaceuticals, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 26, 2026
- Legal name
- ROCKET PHARMACEUTICALS, INC.
- CIK
- 0001281895
Rocket Pharmaceuticals, Inc. · RCKT
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Net income | −$169M | −$222M | −$246M | −$259M | −$223M |
| Diluted EPS | −$2.67 | −$3.26 | −$2.92 | −$2.73 | −$2.01 |
| Cash | |||||
| Cash from operations | −$121M | −$178M | −$195M | −$210M | −$190M |
| Capital expenditure | $7.6M | $8.4M | $16.4M | $5.9M | $0.4M |
| Free cash flow | −$129M | −$187M | −$211M | −$216M | −$190M |
| Share buybacks | $0.0M | — | — | — | — |
| Share count change | 14.2% | 7.8% | 23.3% | 12.9% | 17.2% |
| Debt and strength | |||||
| Cash and short-term investments | $389M | $356M | $373M | $372M | $189M |
| Shareholders' equity | $455M | $490M | $493M | $463M | $277M |
| Current ratio | 17.7x | 9.3x | 7.8x | 9.3x | 6.4x |
| Interest coverage | −56.2x | −120.5x | −138.5x | −144.9x | −122.6x |
| Returns and quality | |||||
| Return on equity | −35.3% | −47.0% | −50.0% | −54.1% | −60.3% |
| Return on tangible equity | −39.9% | −52.2% | −57.3% | −64.9% | −104.8% |
| Piotroski F-score | 2 | 1 | 1 | 2 | 1 |
| Altman Z'' | 10.7 | 5.2 | 2.2 | 0.7 | −10.2 |
Insiders bought, 12 months
$0.0M
1 insider
Insiders sold, 12 months
$0.9M
6 insiders
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Rocket Pharmaceuticals, Inc. · RCKT
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $2.29 a share, the company is worth $262M.
Source: SEC EDGAR XBRL filings (CIK 0001281895). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.